» Articles » PMID: 38535287

Has Extracorporeal Gas Exchange Performance Reached Its Peak?

Overview
Date 2024 Mar 27
PMID 38535287
Authors
Affiliations
Soon will be listed here.
Abstract

Extracorporeal gas exchange therapies evolved considerably within the first three-four decades of their appearance, and have since reached a mature stage, where minor alterations and discrete fine-tuning might offer some incremental improvement. A different approach is introduced here, making use of modern, purely diffusive membrane materials, and taking advantage of the elevated concentration gradient ensuing from gas pressure buildup in the gas chamber of the oxygenator. An assortment of silicone membrane gas exchangers were tested in vitro as per a modified protocol in pursuance of assessing their gas exchange efficiency under both regular and high-pressure aeration conditions. The findings point to a stark performance gain when pressurization of the gas compartment is involved; a 40% rise above atmospheric pressure elevates oxygen transfer rate (OTR) by nearly 30%. Carbon dioxide transfer rate (CTR) does not benefit as much from this principle, yet it retains a competitive edge when higher gas flow/blood flow ratios are employed. Moreover, implementation of purely diffusive membranes warrants a bubble-free circulation. Further optimization of the introduced method ought to pave the way for in vivo animal trials, which in turn may potentially unveil new realms of gas exchange performance for therapies associated with extracorporeal circulation.

References
1.
Robb W . Thin silicone membranes--their permeation properties and some applications. Ann N Y Acad Sci. 1968; 146(1):119-37. DOI: 10.1111/j.1749-6632.1968.tb20277.x. View

2.
Kolobow T, Bowman R . Construction and evaluation of an alveolar membrane artificial heart-lung. Trans Am Soc Artif Intern Organs. 1963; 9:238-43. View

3.
Misra J, Kar B . Formation of a boundary layer in steady-state blood flow. J Biomed Eng. 1988; 10(3):220-4. DOI: 10.1016/0141-5425(88)90002-7. View

4.
Verbelen T, Halwes M, Meyns B . First in vivo assessment of RAS-Q technology as lung support device for pulmonary hypertension. Int J Artif Organs. 2020; 44(4):243-250. PMC: 8041442. DOI: 10.1177/0391398820954217. View

5.
Orizondo R, May A, Madhani S, Frankowski B, Burgreen G, Wearden P . In Vitro Characterization of the Pittsburgh Pediatric Ambulatory Lung. ASAIO J. 2017; 64(6):806-811. PMC: 5995602. DOI: 10.1097/MAT.0000000000000711. View